Clinical Trial Update: Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 study assessing the efficacy of AZD2281 (olaparib) in platinum-sensitive relapsed serous ovarian cancer has completed, with results posted in March 2013…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (AZD2281) (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-03-11